SCOR prend acte de la sentence arbitrale confirmant la validité des traités de rétrocession conclus avec Covéa en juin 2021

An arbitral tribunal confirmed on June 25, 2026 the validity of retrocession treaties between SCOR and Covéa concluded in June 2021, involving the cession of 30% of SCOR's Life & Health portfolio. The tribunal ruled that Covéa should be compensated €488.3 million. After provisions, the impact on SCOR's Q2 2026 net result will be approximately €50 million with no negative effect on solvency ratio or liquidity.